 HOLON, Israel, May 10, 2021 PRNewswire -- Compugen Ltd. Nasdaq: CGEN, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has expanded its research collaboration with Johns Hopkins University to include studies investigating the biology of a novel myeloid target that was computationally-discovered by Compugen. 